Inmode Ltd

Inmode maintains a strong liquidity position with $302.5 million in cash and equivalents, representing 39% of total assets, and a current ratio of 9.88, well above the industry median of 2.1. The company operates with no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. Free cash flow of $93.6 million and operating cash flow of $85.3 million support robust financial flexibility. Profitability metrics show Inmode outperforming industry benchmarks. Return on equity (ROE) of 13.7% exceeds the 10.5% median for medical equipment firms, while return on assets (ROA) of 12.2% surpasses the 8.2% industry median. Gross margin of 78.5% (calculated from $291 million gross profit on $370 million revenue) aligns with the 75-80% range typical for high-margin medical device companies. Geographically, Inmode derives 58% of revenue from North America and 29% from Europe, with the remaining 13% from Asia-Pacific and other regions. The company's product portfolio is concentrated in aesthetic devices (75% of revenue) and gynecological solutions (25%), with no material exposure to hospital-based equipment segments. Revenue growth has accelerated to 22% year-over-year, driven by strong adoption of its radiofrequency and laser platforms. Analysts project 18% revenue growth in the next fiscal year, with price targets averaging $17.00 per share, implying 23% upside from the current $13.83 level. The P/E ratio of 9.34 is 30% below the 13.5 median for the sector, suggesting potential undervaluation. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued new shares in the past 12 months, and diluted shares outstanding remain unchanged at 63.4 million. No material regulatory or litigation risks were identified in recent filings. Recent events include the Q2 2024 earnings call where management highlighted record bookings and expanded distribution in Asia-Pacific. The company also announced a partnership with a major European aesthetic clinic chain to expand its professional channel. No material negative events were disclosed in the last 90 days.